Madison Square Garden Sports Corp.
MSGS is priced for sustained championship economics and clean value creation from the Rangers spin, but the stock already sits near its all-time high while FY2025 profitability, cash flow quality, and valuation do not support $407.17.
MSGS is a classic case of a great asset priced as if nothing can go wrong. The business owns scarce sports franchises with genuine pricing power, and the latest quarter showed exactly why investors pay up when those assets are winning: event revenue rose 43% YoY, sponsorship/signage rose 23%, and AOI improved to $39.6M from -$16.8M. Management also now has a visible strategic catalyst, with the Rangers spin targeted by end of October, and that can keep sentiment firm for a while.
The problem is price, not story. At $407.17, MSGS trades only 7.2% below its $438.93 high and 29.1% above its 200-day average, so the market has already capitalized a large part of the championship and spin narrative. Against that, the full-year numbers are weak. FY2025 revenue was $1.0B, up just 3.4%, while EPS fell 91.8% to -$0.93 and operating margin compressed from 14.2% to 8.4%. The valuation premium is extreme at 9.19x sales versus a 4.2x peer average, and the balance-sheet optics are poor with $1.1B of debt, 150.54x debt/EBITDA, and a 0.50 current ratio.
The case against owning the stock here depends on three points. First, playoff-driven earnings are not a stable base for valuation, and Q4 proved just how much results can swing with postseason inventory. Second, management's own FY27 commentary includes offsetting cost pressure from higher team compensation, luxury tax, and revenue sharing, followed by ~$60M of additional tax expense in FY28 excluding spin effects. Third, the Rangers separation may unlock value, but the market is already paying heavily for that optionality before the transaction is complete and before any standalone trading levels exist.
Conviction is not high because scarcity can overpower spreadsheets in the short run, especially with 63.8% top-three institutional ownership, 16.2% insider ownership, and supportive options positioning. But over a 6-12 month horizon, the burden of proof sits with the bulls at this price. To turn positive, there would need to be evidence that FY27 revenue growth translates into a sustained margin reset well above FY2025's 8.4% and that the post-spin sum-of-the-parts value still clears the current enterprise value by a meaningful margin.
Knicks championship demand proves durable across tickets, suites, sponsorship, F&B, and merchandise, and the Rangers separation deepens the scarcity premium despite weak traditional valuation anchors.
FY27 revenue grows as guided but higher compensation, luxury tax, and revenue sharing offset much of the upside, leaving MSGS valued closer to the engine's blended fair value.
Playoff economics fade, the Rangers spin fails to unlock value, and investors refocus on 8.4% FY2025 operating margin, 150.54x debt/EBITDA, and ~$60M FY28 tax pressure.
Quant call (SELL) diverges from analyst consensus (Strong Buy: 4 buy / 1 hold / 0 sell) — resolve explicitly.
In the short run, the market is a voting machine, but in the long run, it is a weighing machine.
Forward earnings power should improve from the depressed FY2025 EPS of -$0.93, but the market is already paying for a clean rebound before the cost headwinds are absorbed. The moat remains tied to scarcity ownership of marquee New York franchises, premium seating, and sponsor access, but over 3-5 years that moat is still capped by league economics, tax regimes, and venue monetization rather than scalable technology. AI is not a major earnings unlock here, it can help ticket pricing, CRM, and sponsorship analytics, but it does not change the asset intensity or the ceiling on game inventory. With rates still elevated at 4.68% on the 10-year, a trophy-asset premium can persist, but it is harder to justify 9.19x sales for a business with cyclical playoff dependence and explicit FY28 tax drag.
- Valuation is stretched at 9.19x P/S versus a 4.2x peer average, with the engine's blended price target at $196.84, or -51.7% from $407.17.
- Core fundamentals were weak in FY2025 despite revenue of $1.0B, with EPS -$0.93 down 91.8% YoY and operating margin falling to 8.4% from 14.2%.
- The stock already discounts near-term good news, trading 29.1% above the 200-day average and only 7.2% below the $438.93 52-week high after the Knicks title and Rangers spin filing.
- Management expects FY27 revenue growth across all major categories, supported by Knicks title momentum, suite renovations, and season ticket renewals expected to remain above 90%.
- Recent operating momentum improved sharply in Q4, with AOI $39.6M versus -$16.8M YoY, event revenue +43% YoY, and sponsorship/signage +23% YoY.
- The Rangers business spin is now tangible, with the company publicly filing Form 10 and targeting completion by end of October, which could surface hidden asset value.
- Institutional sponsorship of the story is strong, with the top three institutions holding 63.8% and insiders owning 16.2%, limiting float and supporting scarcity value.
- FY2025 quality was poor: Growth Potential 24/100, Cash Flow Quality 20/100, Profitability 2/100, and only $0.1B of FCF against a $9.4B market cap.
- Balance-sheet and liquidity indicators are weak, with current ratio 0.50, total debt $1.1B, and debt/EBITDA 150.54, leaving little room if playoff-driven demand normalizes.
- Management explicitly guided to cost pressure in FY27 from higher team compensation, luxury tax, and revenue sharing, then another ~$60M of incremental tax expense in FY28 excluding spin effects.
- Earnings are volatile and hard to underwrite, with the last six reported quarters including misses of -239.3%, -48.5%, -139.9%, and -83.3% versus consensus.
| Metric | Value | Context |
|---|---|---|
| Current price | $407.17 | Reference point for valuation and scenario analysis |
| Quant price target | $196.84 | Low confidence, -51.7% vs current, basis: sales_quality_blend |
| Valuation method blend | P/S $135.93 | Quality-adjusted $364.82 | DCF $70.28 | Wide spread signals valuation uncertainty, but all methods sit below spot |
| FY2025 revenue | $1.0B | +3.4% YoY, modest growth despite premium demand backdrop |
| FY2025 EPS | -$0.93 | -91.8% YoY, weak profitability despite revenue growth |
| Operating margin | 8.4% | Down from 14.2% in prior FY |
| Net margin | 6.2% | Positive but not supportive of current premium multiple |
| P/S | 9.19x | Versus peer average 4.2x |
| Peer P/E snapshot | 14.7x average | Based on 4 peers, with wide dispersion 8.2x |
| Leverage and liquidity | Debt/EBITDA 150.54x | Total debt $1.1B | Current ratio 0.50 | Weak balance-sheet optics |
| Free cash flow | $0.1B | Against $9.4B market cap, limited cash yield |
| Price action | -7.2% vs 52-week high | +29.1% vs 200-day average | Stock is already elevated into the catalyst window |
The biggest risk to the SELL call is that Knicks title momentum plus the Rangers spin sustain scarcity-driven valuation well above fundamentals, especially with season ticket renewals still expected above 90% and short interest only 6.10%.
The next catalyst is execution on the proposed Rangers spin-off by end of October, along with the market's first read on whether FY27 category growth offsets higher compensation, luxury tax, and revenue-sharing expense.
Ownership is tight, with top-three institutions at 63.8% and insiders at 16.2%, which supports a scarcity premium and can amplify moves when sentiment turns positive. Short interest is only 6.10%, or 1,267,773 shares with 5.3 days-to-cover, enough for squeezes around catalysts but not enough to build a thesis on forced covering. Options positioning is supportive near term, with a positive GEX regime and zero-gamma at $398.41, just 3.53% below spot, which can dampen downside volatility even if fundamentals lag.
Available data does not break FY2025 revenue by business line, so the cleanest operating read is category commentary: management expects FY27 growth across tickets, sponsorship, suites, F&B, and merchandise.
Boosted by premium playoff ticketing and stronger in-arena spend, underscoring how much earnings can swing with postseason inventory.
Partner demand strengthened through the postseason and should benefit further from Knicks title visibility.
The new NHL CBA modestly improves monetizable inventory quality even if the game-count impact is small.
MSGS sees fiscal 27 revenue growth across all major categories, supported by Knicks title momentum and a Rangers spin target by October.
Execution has been mixed, not cleanly strong. On the stale 2024 Q4 call, management said, "we believe we have the opportunity to drive modest ticket revenue growth in fiscal ‘25," and FY2025 did deliver revenue of $1.0B, up 3.4% YoY, which is consistent with modest growth. But profitability deteriorated sharply instead of building off the FY24 AOI of $172.2M and record results, with FY2025 EPS -$0.93 down 91.8% YoY and operating margin down to 8.4% from 14.2%. Management also flagged national media uplift starting FY26 but warned local rights reductions could offset part of it, and the current setup still reflects that rights complexity rather than a clean margin step-up. The recent Q4 was better, $0.28B revenue and $0.04B EBITDA for a 14.0% margin, plus AOI $39.6M versus -$16.8M YoY, but the quarterly beat pattern remains volatile with two large misses in 2026, including -239.3% and -48.5%. Credibility is fair, not high: management generally identifies the right drivers, but the business is too event-sensitive to award a premium for forecast precision.
As we look ahead, we believe our business is poised to deliver revenue growth across all enteric categories in fiscal 27.
We anticipate publicly filing an updated Form 10 statement this week. And currently expect to complete the spin off by the end of October.
Adjusted operating income was $39.6 million as compared to adjusted operating loss of $16.8 million in the prior year quarter which reflected the increases in revenues partially offset by higher SG&A and direct operating expenses.
Looking ahead to the upcoming seasons, we are off to a strong start with season ticket renewals. And we expect our combined season ticket renewal rate to once again reach levels above 90%.
Excluding the impact of the proposed spin off, we currently estimate these changes result in approximately $60 million in additional income tax expense for that fiscal year. that is fiscal year 28.
The moat is franchise scarcity. MSGS owns economically unique sports assets tied to the Knicks and Rangers, with pricing power in premium seating, sponsorship, and local fan demand that weaker entertainment assets cannot replicate. That moat is durable because supply is fixed and New York corporate demand is deep, but it is not infinitely expandable, returns still swing with playoff runs, league cost structures, and media-rights terms.
Capital allocation has been conservative to the point of limited shareholder return, with $0.1B FCF, $0.0B buybacks, $0.0B dividends, and $0.0B capex reported in the deep-dive data. The current strategic priority is structural, not distributive: execute the Rangers spin and keep investing in revenue-yielding suite renovations. That is sensible, but at $9.4B market cap the lack of direct cash return makes the valuation depend almost entirely on asset revaluation and earnings improvement.
Rated SELL, Medium conviction. MSGS owns rare sports assets, and the near-term news flow is favorable, but the stock price already reflects a lot of that upside. At $407.17, investors are paying a very high premium to sales and overlooking weak full-year profitability, light free cash flow, and clear cost headwinds. A view change would require proof that FY27 growth converts into sustained margins materially above 8.4% and that the Rangers spin creates sum-of-the-parts value well beyond the current valuation. Until then, the better call is to avoid chasing a scarcity story near the highs.
≣ Full research note tap to expand
Executive Summary
SELL, Medium conviction. Rated SELL, Medium conviction. The setup is the key issue: MSGS trades at 9.19x sales versus peers at 4.2x, is only 7.2% below its 52-week high, and carries a quant base value of $196.84, even after a strong Q4 helped by Knicks playoff economics. Management's FY27 outlook is directionally positive, but the market is capitalizing a temporary earnings spike and spin-off optimism far more aggressively than the company's FY2025 8.4% operating margin, $0.1B FCF, and highly levered 150.54x debt/EBITDA profile justify.
Investment Thesis
MSGS is a classic case of a great asset priced as if nothing can go wrong. The business owns scarce sports franchises with genuine pricing power, and the latest quarter showed exactly why investors pay up when those assets are winning: event revenue rose 43% YoY, sponsorship/signage rose 23%, and AOI improved to $39.6M from -$16.8M. Management also now has a visible strategic catalyst, with the Rangers spin targeted by end of October, and that can keep sentiment firm for a while.
The problem is price, not story. At $407.17, MSGS trades only 7.2% below its $438.93 high and 29.1% above its 200-day average, so the market has already capitalized a large part of the championship and spin narrative. Against that, the full-year numbers are weak. FY2025 revenue was $1.0B, up just 3.4%, while EPS fell 91.8% to -$0.93 and operating margin compressed from 14.2% to 8.4%. The valuation premium is extreme at 9.19x sales versus a 4.2x peer average, and the balance-sheet optics are poor with $1.1B of debt, 150.54x debt/EBITDA, and a 0.50 current ratio.
The case against owning the stock here depends on three points. First, playoff-driven earnings are not a stable base for valuation, and Q4 proved just how much results can swing with postseason inventory. Second, management's own FY27 commentary includes offsetting cost pressure from higher team compensation, luxury tax, and revenue sharing, followed by ~$60M of additional tax expense in FY28 excluding spin effects. Third, the Rangers separation may unlock value, but the market is already paying heavily for that optionality before the transaction is complete and before any standalone trading levels exist.
Conviction is not high because scarcity can overpower spreadsheets in the short run, especially with 63.8% top-three institutional ownership, 16.2% insider ownership, and supportive options positioning. But over a 6-12 month horizon, the burden of proof sits with the bulls at this price. To turn positive, there would need to be evidence that FY27 revenue growth translates into a sustained margin reset well above FY2025's 8.4% and that the post-spin sum-of-the-parts value still clears the current enterprise value by a meaningful margin.
Key Metrics
| Metric | Value | Context | ||
|---|---|---|---|---|
| Current price | $407.17 | Reference point for valuation and scenario analysis | ||
| Quant price target | $196.84 | Low confidence, -51.7% vs current, basis: sales_quality_blend | ||
| Valuation method blend | P/S $135.93 | Quality-adjusted $364.82 | DCF $70.28 | Wide spread signals valuation uncertainty, but all methods sit below spot |
| FY2025 revenue | $1.0B | +3.4% YoY, modest growth despite premium demand backdrop | ||
| FY2025 EPS | -$0.93 | -91.8% YoY, weak profitability despite revenue growth | ||
| Operating margin | 8.4% | Down from 14.2% in prior FY | ||
| Net margin | 6.2% | Positive but not supportive of current premium multiple | ||
| P/S | 9.19x | Versus peer average 4.2x | ||
| Peer P/E snapshot | 14.7x average | Based on 4 peers, with wide dispersion 8.2x | ||
| Leverage and liquidity | Debt/EBITDA 150.54x | Total debt $1.1B | Current ratio 0.50 | Weak balance-sheet optics |
| Free cash flow | $0.1B | Against $9.4B market cap, limited cash yield | ||
| Price action | -7.2% vs 52-week high | +29.1% vs 200-day average | Stock is already elevated into the catalyst window |
Financial Strength
Financial strength is the weak point in the story. The business remains cash generative on paper with $0.1B of free cash flow, but that is thin relative to a $9.4B equity value and does not offset the poor quality signals in profitability and cash flow. Margin compression from 14.2% to 8.4% in FY2025 matters more than the single-quarter Q4 rebound, because it shows how quickly economics can deteriorate outside the best event mix. The balance-sheet screen is also unattractive, with $1.1B of debt, a 0.50 current ratio, and a mechanically extreme 150.54x debt/EBITDA, which leaves the stock leaning on asset scarcity rather than financial resilience.
Competitive Position
The moat is franchise scarcity. MSGS owns economically unique sports assets tied to the Knicks and Rangers, with pricing power in premium seating, sponsorship, and local fan demand that weaker entertainment assets cannot replicate. That moat is durable because supply is fixed and New York corporate demand is deep, but it is not infinitely expandable, returns still swing with playoff runs, league cost structures, and media-rights terms.
Management & Guidance
Guidance is directionally positive but not cleanly bullish on earnings. Management said, "As we look ahead, we believe our business is poised to deliver revenue growth across all enteric categories in fiscal 27," with support from Knicks title momentum, suite renovations, and combined season-ticket renewals expected to remain above 90%. That is credible on the revenue line given Q4 demand trends and the additional Rangers regular-season home game, but management also flagged higher team compensation, luxury tax, and revenue-sharing expense in FY27, then about $60M of additional income tax expense in FY28 excluding spin effects. The result is a guide that supports growth, but not one that fully supports the current equity price without further margin upside.
Segment Analysis
- Product/segment disclosure (Not separately provided): Available data does not break FY2025 revenue by business line, so the cleanest operating read is category commentary: management expects FY27 growth across tickets, sponsorship, suites, F&B, and merchandise.
- Event-driven revenue (Q4 event revenue growth +43% YoY): Boosted by premium playoff ticketing and stronger in-arena spend, underscoring how much earnings can swing with postseason inventory.
- Sponsorship and signage (Q4 growth +23% YoY): Partner demand strengthened through the postseason and should benefit further from Knicks title visibility.
- Team mix and game inventory (Rangers FY27 home-game mix +1 regular season / -1 preseason): The new NHL CBA modestly improves monetizable inventory quality even if the game-count impact is small.
Capital Allocation
Capital allocation has been conservative to the point of limited shareholder return, with $0.1B FCF, $0.0B buybacks, $0.0B dividends, and $0.0B capex reported in the deep-dive data. The current strategic priority is structural, not distributive: execute the Rangers spin and keep investing in revenue-yielding suite renovations. That is sensible, but at $9.4B market cap the lack of direct cash return makes the valuation depend almost entirely on asset revaluation and earnings improvement.
Management Execution & Track Record
Execution has been mixed, not cleanly strong. On the stale 2024 Q4 call, management said, "we believe we have the opportunity to drive modest ticket revenue growth in fiscal ‘25," and FY2025 did deliver revenue of $1.0B, up 3.4% YoY, which is consistent with modest growth. But profitability deteriorated sharply instead of building off the FY24 AOI of $172.2M and record results, with FY2025 EPS -$0.93 down 91.8% YoY and operating margin down to 8.4% from 14.2%. Management also flagged national media uplift starting FY26 but warned local rights reductions could offset part of it, and the current setup still reflects that rights complexity rather than a clean margin step-up. The recent Q4 was better, $0.28B revenue and $0.04B EBITDA for a 14.0% margin, plus AOI $39.6M versus -$16.8M YoY, but the quarterly beat pattern remains volatile with two large misses in 2026, including -239.3% and -48.5%. Credibility is fair, not high: management generally identifies the right drivers, but the business is too event-sensitive to award a premium for forecast precision.
Positioning & Flows
Ownership is tight, with top-three institutions at 63.8% and insiders at 16.2%, which supports a scarcity premium and can amplify moves when sentiment turns positive. Short interest is only 6.10%, or 1,267,773 shares with 5.3 days-to-cover, enough for squeezes around catalysts but not enough to build a thesis on forced covering. Options positioning is supportive near term, with a positive GEX regime and zero-gamma at $398.41, just 3.53% below spot, which can dampen downside volatility even if fundamentals lag.
Bull Case
- Management expects FY27 revenue growth across all major categories, supported by Knicks title momentum, suite renovations, and season ticket renewals expected to remain above 90%.
- Recent operating momentum improved sharply in Q4, with AOI $39.6M versus -$16.8M YoY, event revenue +43% YoY, and sponsorship/signage +23% YoY.
- The Rangers business spin is now tangible, with the company publicly filing Form 10 and targeting completion by end of October, which could surface hidden asset value.
- Institutional sponsorship of the story is strong, with the top three institutions holding 63.8% and insiders owning 16.2%, limiting float and supporting scarcity value.
Bear Case
- FY2025 quality was poor: Growth Potential 24/100, Cash Flow Quality 20/100, Profitability 2/100, and only $0.1B of FCF against a $9.4B market cap.
- Balance-sheet and liquidity indicators are weak, with current ratio 0.50, total debt $1.1B, and debt/EBITDA 150.54, leaving little room if playoff-driven demand normalizes.
- Management explicitly guided to cost pressure in FY27 from higher team compensation, luxury tax, and revenue sharing, then another ~$60M of incremental tax expense in FY28 excluding spin effects.
- Earnings are volatile and hard to underwrite, with the last six reported quarters including misses of -239.3%, -48.5%, -139.9%, and -83.3% versus consensus.
Valuation & Price Target
Engine price target $196.84 (-51.7% vs current), Low confidence.
- P/S Multiple: $135.93 (45% weight)
- Quality-adjusted: $364.82 (20% weight)
- DCF: $70.28 (5% weight)
The rating aligns with the quant baseline of SELL, but with Medium rather than low conviction because the near-term setup has real support from the Knicks title, strong Q4 demand, and a live spin-off catalyst. Even so, the numbers do not support $407.17: the stock trades at 9.19x sales versus peers at 4.2x, FY2025 operating margin fell to 8.4%, FCF was only $0.1B, and leverage and liquidity screens are weak at 150.54x debt/EBITDA and 0.50 current ratio. The engine's $196.84 target is low confidence because peer comparability is messy and dispersion is wide at 8.2x, but the broad message is still right, valuation is pricing the upside far more aggressively than fundamentals. Sell-side consensus is Strong Buy from only 5 firms, which is low-signal context here and not persuasive against the company's actual earnings volatility and current multiple.
Risk Assessment
Risk score 58/100 (Moderate). The biggest risk to the SELL call is that Knicks title momentum plus the Rangers spin sustain scarcity-driven valuation well above fundamentals, especially with season ticket renewals still expected above 90% and short interest only 6.10%.
The Bottom Line
Rated SELL, Medium conviction. MSGS owns rare sports assets, and the near-term news flow is favorable, but the stock price already reflects a lot of that upside. At $407.17, investors are paying a very high premium to sales and overlooking weak full-year profitability, light free cash flow, and clear cost headwinds. A view change would require proof that FY27 growth converts into sustained margins materially above 8.4% and that the Rangers spin creates sum-of-the-parts value well beyond the current valuation. Until then, the better call is to avoid chasing a scarcity story near the highs.
Go deeper in the app
Live charts, options analytics, the full earnings-call breakdown, price alerts, and every other stock — updated in real time.
Get Tickr